CAP accreditation is awarded to laboratories that meet the highest standards of quality, accuracy and consistency
OncoStem Diagnostics, an oncology focussed company that enables personalised breast cancer treatment has been awarded accreditation from the College of American Pathologists (CAP) for its laboratory in Bengaluru. CAP accreditation is awarded to laboratories that meet the highest standards of quality, accuracy and consistency.
The College of American Pathologists (CAP) is a leading US-based organisation of board-certified pathologists that serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. CAP’s accredition programmes is widely considered the leader in laboratory quality assurance.Designed to go well beyond regulatory compliance, the programme helps laboratories achieve the highest standards of excellence to positively impact patient care
On the occasion, Dr Manjiri Bakre, CEO and Founder, OncoStem Diagnostics said, “We are pleased to receive this accreditation for the superior quality of laboratory services that we provide. CAP accreditation validates our continued efforts to provide accurate results and prompt service to our patients under stringent quality processes. This recognition by CAP augments our focus on the vision to help early stage cancer patients towards optimal treatment planning through reliable and accurate results”
OncoStem’s CanAssist Breast is a proteomic based test that assesses the expression of metastasis-related biomarkers to predict the probability of recurrence of invasive breast carcinoma in early stage ER+/Her2- breast cancer patients. It categorises the risk of cancer recurrence clearly as either ‘low or high’ with no grey area in between.This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. It makes customised treatment possible by either avoiding or shortening chemotherapy treatment cycles in low-risk patients and by identifying high risk patients who would benefit from the addition of chemotherapy.